Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - Clearside Biomedical reported a quarterly loss of $0.10 per share, better than the Zacks Consensus Estimate of a loss of$0.13, representing an earnings surprise of 23.08% [1] - The company posted revenues of $0.31 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 13.33$6.35 million year-over-year [2] - The stock has increased approximately 7.4% since the beginning of the year, contrasting with the S&P 500's decline of -2.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of$0.2 million, and for the current fiscal year, it is -$0.54 on revenues of$5.23 million [7] - The Medical - Biomedical and Genetics industry is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]